Intra-Cellular Therapies Inc
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The … Read more
Intra-Cellular Therapies Inc - Asset Resilience Ratio
Intra-Cellular Therapies Inc (ITCI) has an Asset Resilience Ratio of 50.78% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Intra-Cellular Therapies Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Intra-Cellular Therapies Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $694.12 Million | 50.78% |
| Total Liquid Assets | $694.12 Million | 50.78% |
Asset Resilience Insights
- Very High Liquidity: Intra-Cellular Therapies Inc maintains exceptional liquid asset reserves at 50.78% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Intra-Cellular Therapies Inc Industry Peers by Asset Resilience Ratio
Compare Intra-Cellular Therapies Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Intra-Cellular Therapies Inc (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Intra-Cellular Therapies Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 50.78% | $694.12 Million | $1.37 Billion | +2.70pp |
| 2023-12-31 | 48.08% | $350.17 Million | $728.29 Million | -10.65pp |
| 2022-12-31 | 58.73% | $443.29 Million | $754.78 Million | -6.58pp |
| 2021-12-31 | 65.31% | $319.97 Million | $489.92 Million | -17.97pp |
| 2020-12-31 | 83.28% | $597.40 Million | $717.31 Million | +36.95pp |
| 2019-12-31 | 46.33% | $116.37 Million | $251.19 Million | -35.58pp |
| 2018-12-31 | 81.91% | $292.58 Million | $357.21 Million | -8.56pp |
| 2017-12-31 | 90.47% | $426.54 Million | $471.49 Million | +4.21pp |
| 2016-12-31 | 86.26% | $335.46 Million | $388.90 Million | -2.16pp |
| 2015-12-31 | 88.42% | $428.04 Million | $484.10 Million | +36.31pp |
| 2014-12-31 | 52.11% | $68.32 Million | $131.11 Million | +46.91pp |
| 2013-12-31 | 5.20% | $2.00 Million | $38.45 Million | -12.45pp |
| 2012-12-31 | 17.66% | $3.50 Million | $19.82 Million | -21.34pp |
| 2011-12-31 | 38.99% | $9.20 Million | $23.59 Million | -- |